Preclinical Research

How GLP-1 Agonists May Protect the Brain: The Proposed Mechanisms, and What the Evidence Actually Shows

GLP-1 receptor agonists, known for diabetes and obesity treatment, show promise for neuroprotection based on preclinical studies. However, human trial evidence is mixed, and the exact mechanisms, whether direct brain effects or indirect metabolic improvements, are still under investigation.